Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline
10:45am, Monday, 08'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securiti
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management and
Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline
07:30am, Monday, 08'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securiti
LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Am
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders
05:45am, Monday, 08'th Apr 2024
NEW YORK , April 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit. CLASS
NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, NY / ACCESSWIRE / April 7, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securiti
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
02:21pm, Thursday, 04'th Apr 2024
Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%.
Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market
07:43am, Thursday, 04'th Apr 2024
The decision to remove Relyvrio from the market comes after the drug failed a Phase 3 trial.
Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets
07:12am, Thursday, 04'th Apr 2024
Amylyx Pharmaceuticals said on Thursday it would withdraw its amyotrophic lateral sclerosis (ALS) drug from the U.S. and Canada markets after the treatment failed in a crucial late-stage trial.
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
01:36pm, Monday, 11'th Mar 2024
Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.
Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.
08:00am, Sunday, 10'th Mar 2024
Amylyx's ALS drug failed a late-stage trial, raising questions about the future of the drug and the company itself.
Amylyx's ALS Drug Fails Trial, Raising Questions About Company's Future
10:20am, Friday, 08'th Mar 2024
Relyvrio, which is sold under the name Albrioza in Canada, is Amylyx's only product.
Amylyx's ALS drug fails in late-stage confirmatory study
07:10am, Friday, 08'th Mar 2024
Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.
The Top 3 Biotech Stocks to Buy in March 2024
02:45pm, Wednesday, 06'th Mar 2024
Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.
